<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763161</url>
  </required_header>
  <id_info>
    <org_study_id>BMR_2021_2</org_study_id>
    <nct_id>NCT04763161</nct_id>
  </id_info>
  <brief_title>Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Case-control Study</brief_title>
  <acronym>NEUTROSURGERY</acronym>
  <official_title>Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the NEUTROSURGERY study is to describe the local and locoregional&#xD;
      immuno-inflammatory activity in patients suffering from malignant sylvian ischaemic cerebral&#xD;
      accident and treated with decompressive hemicraniectomy compared to a control population of&#xD;
      patients to be operated on in neurosurgery for another neurosurgical pathology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>neutrophil polynuclear cells levels</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ischemic Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <description>Patients suffering from malignant sylvian ischaemic cerebral accident and treated with decompressive hemicraniectomy.&#xD;
Intervention is decompressive hemicraniectomy in the context of a malignant sylvian ischaemic cerebral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients not suffering from AIC, hospitalised in neurosurgery for another reason,&#xD;
Patients to be opered on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Decompressive hemicraniectomy</intervention_name>
    <description>Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neurosurgical operation</intervention_name>
    <description>neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population concerns patients suffering from malignant sylvian ischaemic cerebral&#xD;
        accident and treated with decompressive hemicraniectomy. Eligibility will be assessed as&#xD;
        soon as the first results of the MRI or brain scan carried out as part of the thrombolysis&#xD;
        alert by the interventional neurologist or neuroradiologist triggering the treatment, in&#xD;
        front of a large ischaemic cerebral accident (&gt;145 ml).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Patients:&#xD;
&#xD;
          -  Collegial indication given by a neurologist, a neuroreanimator and a neurosurgeon for&#xD;
             HD in the context of a malignant sylvian AIC.&#xD;
&#xD;
        Inclusion Criteria Control:&#xD;
&#xD;
        - For neurosurgical operations in which cranial, meningeal, vascular (branch of the middle&#xD;
        meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.&#xD;
&#xD;
        Non-inclusion Criteria Patients:&#xD;
&#xD;
          -  HD carried out in a context of acute cerebral haemorrhage&#xD;
&#xD;
          -  Pre-existing neurological disability: modified Rankin score &gt; 2&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
        Non-inclusion Criteria Controls:&#xD;
&#xD;
          -  Patient to be operated on for an acute vascular condition: meningeal haemorrhage,&#xD;
             subdural or extradural haemorrhage, intra parenchymal haemorrhage.&#xD;
&#xD;
          -  Patient operated on for an osteomeningeal pathology present at the approach site.&#xD;
&#xD;
          -  Patient operated on for an infectious cranial or neuro-meningeal pathology.&#xD;
&#xD;
          -  Patient to be operated on as a result of an intracranial traumatic condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Dr Maier</last_name>
    <phone>0148036454</phone>
    <email>bmaier@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Dr Yavchitz</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

